Xuelian Wei
- Infectious Diseases top 0.5%
- Virology top 0.5%
- Emergency Medicine top 0.5%
- Epidemiology top 10%
- Molecular Biology
- Co-authors
- Jürgen K. RockstrohAndrew ChengKirsten WhiteHal MartinChloe OrkinPaul E. SaxEdwin DeJesusDiana M. Brainard
- Topics
- HIV/AIDS drug development and treatment (20 papers)HIV Research and Treatment (14 papers)HIV/AIDS Research and Interventions (10 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Xuelian Wei
31 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 87
- Infectious Diseases 1.6k
- Virology 1.0k
- Emergency Medicine 886
- Epidemiology 254
- Molecular Biology 194
Countries citing papers authored by Xuelian Wei
This map shows the geographic impact of Xuelian Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuelian Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuelian Wei more than expected).
Fields of papers citing papers by Xuelian Wei
This network shows the impact of papers produced by Xuelian Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuelian Wei. The network helps show where Xuelian Wei may publish in the future.
Co-authorship network of co-authors of Xuelian Wei
This figure shows the co-authorship network connecting the top 25 collaborators of Xuelian Wei. A scholar is included among the top collaborators of Xuelian Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuelian Wei. Xuelian Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathybreakdown → | 51 |
| 2 | 15 | |
| 3 | 1 | |
| 4 | 93 | |
| 5 | 116 | |
| 6 | 99 | |
| 7 | 7 | |
| 8 | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialbreakdown → | 257 |
| 9 | 10 | |
| 10 | 72 | |
| 11 | 10 | |
| 12 | Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study | 12 |
| 13 | 158 | |
| 14 | 1 | |
| 15 | 34 | |
| 16 | 97 | |
| 17 | 256 | |
| 18 | 21 | |
| 19 | 25 | |
| 20 | Salivary oral cancer transcriptome biomarkers (SOCTB) for clinical detection | 2 |
About Xuelian Wei
Xuelian Wei is a scholar working on Virology, Infectious Diseases and Nephrology, having authored 33 papers that have together received 2.0k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (20 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (10 papers). The work is most often cited by research in Virology (1.0k citations), Emergency Medicine (886 citations) and Infectious Diseases (1.6k citations). Xuelian Wei has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Jürgen K. Rockstroh, Andrew Cheng, Kirsten White, Hal Martin, Chloe Orkin, Paul E. Sax, Edwin DeJesus, Diana M. Brainard, Frank A. Post and Joseph Gathe. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.